Metylotestosteron: interakcje

These drugs include, but are not limited to, the following: the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, phenytoin the androgen receptor inhibitor enzalutamide the antimycobacterials rifampin, rifapentine the cytotoxic agent mitotane St. (etykieta leku Dorawiryna, Przeciwwskazania)

Because of the ability of Type II 5α-reductase inhibitors to inhibit the conversion of testosterone to 5α-dihydrotestosterone (DHT), finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant female who receives finasteride. (etykieta leku Finasteryd, Przeciwwskazania)

CONTRAINDICATIONS: Precocious puberty, prostatic carcinoma or other androgen-dependent neoplasm, prior allergic reaction to HCG. (etykieta leku Gonadotropina kosmówkowa, Przeciwwskazania)

To date, epidemiologic studies and randomized controlled trials have been inconclusive for determining the risk of major adverse cardiovascular events (MACE), such as non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death, with the use of testosterone compared to non-use. (etykieta leku Metylotestosteron, Ostrzeżenia)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (etykieta leku Metylotestosteron, Interakcje z innymi lekami)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (etykieta leku Metylotestosteron, Interakcje z innymi lekami)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (etykieta leku Metylotestosteron, Ostrzeżenia)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (etykieta leku Metylotestosteron, Ostrzeżenia)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (etykieta leku Metylotestosteron, Ostrzeżenia)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (etykieta leku Metylotestosteron, Interakcje z innymi lekami)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (etykieta leku Metylotestosteron, Ostrzeżenia)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (etykieta leku Metylotestosteron, Ostrzeżenia)

PRECAUTIONS General Induction of androgen secretion by hCG may cause fluid retention. (etykieta leku Choriogonadotropina alfa, Środki ostrożności)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (etykieta leku Metylotestosteron, Ostrzeżenia)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (etykieta leku Metylotestosteron, Interakcje z innymi lekami)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (etykieta leku Metylotestosteron, Ostrzeżenia)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (etykieta leku Metylotestosteron, Ostrzeżenia)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (etykieta leku Metylotestosteron, Ostrzeżenia)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (etykieta leku Metylotestosteron, Interakcje z innymi lekami)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (etykieta leku Metylotestosteron, Interakcje z innymi lekami)

Free hormone concentrations, such as testosterone and estradiol, may be decreased. (etykieta leku Estradiol + noretysteron, Ostrzeżenia i środki ostrożności)

Free hormone concentrations, such as testosterone and estradiol, may be decreased. (etykieta leku Estrogeny skoniugowane, Środki ostrożności)

Free hormone concentrations, such as testosterone and estradiol, may be decreased. (etykieta leku Estrogeny skoniugowane + bazedoksyfen, Ostrzeżenia i środki ostrożności)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (etykieta leku Metylotestosteron, Ostrzeżenia)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (etykieta leku Metylotestosteron, Ostrzeżenia)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (etykieta leku Metylotestosteron, Ostrzeżenia)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (etykieta leku Metylotestosteron, Ostrzeżenia)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (etykieta leku Metylotestosteron, Ostrzeżenia)

For Men : Clinical monitoring for spermatogenesis utilizes the following indirect or direct measures: Serum testosterone level Semen analysis 5.11 FOLLISTIM Pen The FOLLISTIM Pen is intended only for use with FOLLISTIM AQ Cartridge. (etykieta leku Folitropina, Ostrzeżenia i środki ostrożności)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (etykieta leku Metylotestosteron, Interakcje z innymi lekami)

…medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H 2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs… (etykieta leku Glimepiryd, Interakcje z innymi lekami)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (etykieta leku Goserelina, Ostrzeżenia i środki ostrożności)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (etykieta leku Metylotestosteron, Ostrzeżenia)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (etykieta leku Metylotestosteron, Interakcje z innymi lekami)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (etykieta leku Metylotestosteron, Ostrzeżenia)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (etykieta leku Metylotestosteron, Interakcje z innymi lekami)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (etykieta leku Metylotestosteron, Interakcje z innymi lekami)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (etykieta leku Metylotestosteron, Interakcje z innymi lekami)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (etykieta leku Metylotestosteron, Interakcje z innymi lekami)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (etykieta leku Metylotestosteron, Interakcje z innymi lekami)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (etykieta leku Metylotestosteron, Interakcje z innymi lekami)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (etykieta leku Metylotestosteron, Ostrzeżenia)

Tumor Flare: Increased serum testosterone (~ 50% above baseline) may occur when initiating treatment with LUPRON DEPOT. (etykieta leku Leuprorelina, Ostrzeżenia i środki ostrożności)

Androgens/Anabolic Steroids Asparaginase Glucocorticoids Slow-Release Nictonic Acid These drugs may decrease serum TBG concentration. (etykieta leku Lewotyroksyna, Interakcje z innymi lekami)

Androgens/Anabolic Steroids Asparaginase Glucocorticoids Slow-Release Nicotinic Acid These drugs may decrease serum TBG concentration. (etykieta leku Liotyronina, Interakcje z innymi lekami)

However, clinical studies have shown that lovastatin does not reduce basal plasma cortisol concentration or impair adrenal reserve, and does not reduce basal plasma testosterone concentration. (etykieta leku Lowastatyna, Interakcje z innymi lekami)

The following laboratory tests may be affected by progestins including MPA Injectable Suspension, USP: (a) Plasma and urinary steroid levels are decreased (e.g., progesterone, estradiol, pregnanediol, testosterone, cortisol). (etykieta leku Medroksyprogesteron, Interakcje z innymi lekami)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (etykieta leku Metylotestosteron, Ostrzeżenia)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (etykieta leku Metylotestosteron, Ostrzeżenia)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (etykieta leku Metylotestosteron, Ostrzeżenia)

…anti-diabetic medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs… (etykieta leku Pioglitazon + glimepiryd, Interakcje z innymi lekami)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (etykieta leku Metylotestosteron, Ostrzeżenia)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (etykieta leku Metylotestosteron, Ostrzeżenia)

Reproductive effects: Include decreased testosterone and increased prolactin levels. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (etykieta leku Metylotestosteron, Interakcje z innymi lekami)

Abiraterone: Spironolactone binds to the androgen receptor and may increase prostate‑specific antigen (PSA) levels in abiraterone-treated prostate cancer patients. (etykieta leku Spironolakton + hydrochlorotiazyd, Interakcje z innymi lekami)

Hypercalcemia in Patients with Metastatic Breast Cancer As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. (etykieta leku Tamoksyfen, Ostrzeżenia i środki ostrożności)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (etykieta leku Metylotestosteron, Ostrzeżenia)

Tumor Flare: Transient increase in serum testosterone levels can occur within the first few weeks of treatment. (etykieta leku Tryptorelina, Ostrzeżenia i środki ostrożności)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (etykieta leku Metylotestosteron, Interakcje z innymi lekami)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (etykieta leku Metylotestosteron, Interakcje z innymi lekami)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)

Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. (etykieta leku Metylotestosteron, Środki ostrożności)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)

Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. (etykieta leku Metylotestosteron, Środki ostrożności)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)

Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. (etykieta leku Metylotestosteron, Środki ostrożności)

Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. (etykieta leku Metylotestosteron, Środki ostrożności)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)

In addition to discontinuation of the drug, diuretic therapy may be required. (etykieta leku Metylotestosteron, Ostrzeżenia)